Jump to top menu Jump to main menu Jump to content
Research project default image
Research project

Energy Based Drug Delivery of Bleomycin in Keloids and Hypertrophic Scars

Using novel energy-based devices such as fractional ablative lasers and electronic controlled pneumatic injection devices we aim to the enhance the treatment of keloids and hypertrophic scars.

What we do

About our project

What is the motivation for this research?

Keloids and hypertrophic scars are dysregulated immune responses to cutaneous wound healing and can be associated with substantial physical and psychological distress. Current first-line therapy is triamcinolone administered via conventional needle injections, however, this is associated with (severe) pain and frequent recurrences. Research suggests that bleomycin, an antineoplastic antibiotic, is a promising treatment option and reduces the number of recurrences in keloids and hypertrophic scars. Dermal bleomycin administration using energy-based drug delivery techniques, such as electronic pneumatic injection or ablative fractional laser, could be more effective, faster and less painful treatment options for keloids and hypertrophic scars.

 

What is the aim?

We aim to investigate the working mechanism, efficacy, and tolerability of energy-based drug delivery of bleomycin in keloids and hypertrophic scars.

 

How will you perform this study?

By systematic literature searches, translational research and clinical research with healthy volunteers and patients, in collaboration with national and international experts in the field of energy-based drug delivery in dermatology.

 

What do you hope to achieve?

To achieve a better understanding of energy-based drug delivery of bleomycin in an ex vivo and in vivo research setting. Additionally, to reduce the number of treatments and recurrences in keloids and hypertrophic scars, while improving patient satisfaction.

Collaborations

Internal collaborations

Department of Pathology, Erasmus MC

External collaborations

Dr. Albert Wolkerstorfer, MD, PhD, Department of Dermatology, Amsterdam UMC, Amsterdam, The Netherlands (www.amsterdamumc.nl/)

Prof. Dr. Merete Haedersdal, MD, PhD, DMSc, Department of Dermatology, Bispebjerg hospital, Copenhagen, Denmark (www.bispebjerghospital.dk/english)

Dr. Robert Rissmann, PharmD, PhD, Center for Human Drug Research, Leiden, The Netherlands. (www.chdr.nl)

 

 

Our team

Martijn van Doorn, MD, PhD, dermatologist – clinical pharmacologist

Prof. Errol Prens, MD, PhD, dermatologist - immunologist

Jeffrey Damman, MD, PhD, pathologist

contact: l.bik@erasmusmc.nl

 

 

Principal Investigators

Project Leaders